Self-injection Devices Market: Current Analysis and Forecast (2022-2028)

Self-injection devices are medical devices designed to allow patients to self-administer medications, such as insulin, growth hormones, and other biologics. These devices are typically used by patients who require regular injections and are designed to be easy to use, portable, and discreet. The growth of the market is mainly driven by the factors such as the increasing prevalence of chronic diseases requiring injectable treatments. For instance, as per the International Diabetes Federation, Approximately 537 million adults between 20 & 79 years are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.

The Self-injection Devices Market is expected to grow at a strong CAGR of 6% during the forecast period owing to the increasing adoption of advanced technology in the healthcare sector. For instance, in May 2022, Jabil Healthcare Announces the Launch of the Qfinity™ Autoinjector Platform, a Reusable Drug Delivery Device with Broad Applicability.

Based on product, the market is segmented into autoinjectors, pen injectors, wearable injectors, and needle-free injectors. Pen injectors held dominating share in 2021. Pen injectors are medical devices that are used to deliver medication subcutaneously (under the skin) or intramuscularly (into the muscle). They consist of a pen-like device that contains a pre-filled cartridge or a replaceable insulin reservoir, and a needle that is attached to the end of the pen. The convenient usage of the self-injection of these devices, along with the increasing prevalence of chronic diseases attributes to the growth of the segment.

On the basis of usability, the market is bifurcated into disposable and reusable. The disposable segment held a significant share of the self-injection devices market in 2021. This is mainly due to the fact that disposable self-injection devices being sterile and designed for single use, which reduces the risk of infection or contamination. This is particularly important for patients who have compromised immune systems or are at higher risk for infection.

Based on application, the market is segmented into cancer, autoimmune disorders, hormonal disorders, pain management, and others. The cancer had the largest share in 2021 in the self-injection devices market. The higher prevalence of cancer is responsible for the increasing demand for self-injection devices. For instance, as per the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease.

For a better understanding of the market adoption of the self-injection devices industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America dominated the self-injection devices market in 2021 due to the rising geriatric population and increased frequency of diseases among them. Furthermore, the presence of major market players, along with the well-established healthcare infrastructure in the region attributed to the major share of the self-injection devices market in North America.

Some of the major players operating in the market include: Ypsomed AG; BD; Gerresheimer AG; Halozyme, Inc.; Haselmeier; NuGen Medical Devices; Owen Mumford Limited; SHL Medical AG; Pfizer Inc.; and Amgen Inc.